Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Limited Use, Reason for Use code 667 requiredMarketed · checked November 17, 2026
StatusLimited Use, Reason for Use code 667 required
Write on scriptReason for Use code 667 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ontario Limited Use criteria, code 667
Reason for Use code 667
For the treatment of adult patients with type 2 diabetes when adequate glycemic control is not achieved on the maximum tolerated dose of metformin or where metformin is contraindicated or inappropriate.
Semaglutide is not funded in combination with another glucagon-like peptide-1 receptor agonist (GLP-1 RA) or dipeptidyl peptidase-4 (DPP-4) inhibitor.
Injectable semaglutide is not funded in combination with oral semaglutide. Coverage is only provided for one dosage format.
Reimbursed dose: As per the product monograph
Coverage limit:
LU Authorization Period: Indefinite
1 brand, same coverage
Apo-Semaglutide Injection · DIN 02568020
Manufacturer: Apotex Inc.; listing date 2026-06-30
Health Canada: Marketed since 2026-05-14 · brand APO-SEMAGLUTIDE INJECTION · ATC A10BJ06 SEMAGLUTIDE · form Solution · route Subcutaneous · ingredients SEMAGLUTIDE 0.68 MG/ML · company Apotex inc · schedule Prescription
Apo-Semaglutide Injection: Formulary list price $78.14 per unit (the source does not state the unit; exact figure $78.1410). What the ministry pays, not the patient.
Ministry pays: $78.1410 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 02568020: Apo-Semaglutide Injection
Raw flags: insOH=Y, sec12=Y, sec3=Y
Item: 682006009; group id 759; item number 1864; lccId 00382; manufacturer id APX
Source form: Inj Sol - Pref Pen 3mL Pk; strength: 0.68mg/mL
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; diabetes medication flag
Source prices (unrounded): $78.1410; ministry $78.1410
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02568020
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=107038Interchangeable products
Ozempic · DIN 02540258 · $78.1410
Shortage status: active shortage (reported September 15, 2026, last updated September 17, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02568020
Limited Use, Reason for Use code 667 requiredMarketed · checked November 17, 2026
StatusLimited Use, Reason for Use code 667 required
Write on scriptReason for Use code 667 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ontario Limited Use criteria, code 667
Reason for Use code 667
For the treatment of adult patients with type 2 diabetes when adequate glycemic control is not achieved on the maximum tolerated dose of metformin or where metformin is contraindicated or inappropriate.
Semaglutide is not funded in combination with another glucagon-like peptide-1 receptor agonist (GLP-1 RA) or dipeptidyl peptidase-4 (DPP-4) inhibitor.
Injectable semaglutide is not funded in combination with oral semaglutide. Coverage is only provided for one dosage format.
Reimbursed dose: As per the product monograph
Coverage limit:
LU Authorization Period: Indefinite
Savings card: innoviCares lists Ozempic (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up. (innovicares.ca ↗)
1 brand, same coverage
Ozempic · DIN 02540258
Manufacturer: Novo Nordisk Canada Inc; listing date 2024-01-31
Health Canada: Marketed since 2023-12-22 · brand OZEMPIC · ATC A10BJ06 SEMAGLUTIDE · form Solution · route Subcutaneous · ingredients SEMAGLUTIDE 0.68 MG/ML · company Novo nordisk canada inc · schedule Schedule d, Prescription
DIN 02540258: Ozempic
Raw flags: insOH=Y, sec12=Y, sec3=Y
Item: 682006009; group id 759; item number 1864; lccId 00382; manufacturer id NOO
Source form: Inj Sol - Pref Pen 3mL Pk; strength: 0.68mg/mL
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; diabetes medication flag
Source prices (unrounded): $227.9400; ministry $78.1410
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02540258
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102895Interchangeable products
Apo-Semaglutide Injection · DIN 02568020 · $78.1410
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02540258
Limited Use, Reason for Use code 666 requiredMarketed · checked November 17, 2026
StatusLimited Use, Reason for Use code 666 required
Write on scriptReason for Use code 666 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ontario Limited Use criteria, code 666
Reason for Use code 666
For the treatment of adult patients with type 2 diabetes when adequate glycemic control is not achieved on the maximum tolerated dose of metformin or where metformin is contraindicated or inappropriate.
Semaglutide is not funded in combination with another glucagon-like peptide-1 receptor agonist (GLP-1 RA) or dipeptidyl peptidase-4 (DPP-4) inhibitor.
Injectable semaglutide is not funded in combination with oral semaglutide. Coverage is only provided for one dosage format.
Reimbursed dose: As per the product monograph
Coverage limit:
LU Authorization Period: Indefinite
1 brand, same coverage
Semaglutide Injection · DIN 02567806
Manufacturer: Dr. Reddy's Laboratories Inc.; listing date 2026-06-30
Health Canada: Marketed since 2026-05-06 · brand SEMAGLUTIDE INJECTION · ATC A10BJ06 SEMAGLUTIDE · form Solution · route Subcutaneous · ingredients SEMAGLUTIDE 1.34 MG/ML · company Dr reddy's laboratories ltd · schedule Prescription
Semaglutide Injection: Formulary list price $78.14 per unit (the source does not state the unit; exact figure $78.1410). What the ministry pays, not the patient.
Ministry pays: $78.1410 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 02567806: Semaglutide Injection
Raw flags: insOH=Y, sec12=Y, sec3=Y
Item: 682006002; group id 760; item number 1865; lccId 00383; manufacturer id DRR
Source form: Inj Sol-Pref Pen 1.5mL Pk; strength: 1.34mg/mL
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; diabetes medication flag
Source prices (unrounded): $78.1410; ministry $78.1410
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02567806
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=107018Interchangeable products
Ozempic · DIN 02471477 · $78.1410
Shortage status: active shortage (reported July 20, 2026, last updated September 16, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02567806
Limited Use, Reason for Use code 665 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 665 required
Write on scriptReason for Use code 665 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ontario Limited Use criteria, code 665
Reason for Use code 665
For the treatment of adult patients with type 2 diabetes when adequate glycemic control is not achieved on the maximum tolerated dose of metformin or where metformin is contraindicated or inappropriate.
Semaglutide is not funded in combination with another glucagon-like peptide-1 receptor agonist (GLP-1 RA) or dipeptidyl peptidase-4 (DPP-4) inhibitor.
Injectable semaglutide is not funded in combination with oral semaglutide. Coverage is only provided for one dosage format.
Reimbursed dose: As per the product monograph
Coverage limit:
LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Semaglutide Injection · DIN 02568012
Manufacturer: Apotex Inc.; listing date 2026-06-30
Health Canada: Marketed since 2026-05-14 · brand APO-SEMAGLUTIDE INJECTION · ATC A10BJ06 SEMAGLUTIDE · form Solution · route Subcutaneous · ingredients SEMAGLUTIDE 1.34 MG/ML · company Apotex inc · schedule Prescription
Apo-Semaglutide Injection: Formulary list price $78.14 per unit (the source does not state the unit; exact figure $78.1410). What the ministry pays, not the patient.
Ministry pays: $78.1410 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 02568012: Apo-Semaglutide Injection
Raw flags: insOH=Y, sec12=Y, sec3=Y
Item: 682006001; group id 761; item number 1866; lccId 00384; manufacturer id APX
Source form: Inj Sol-Pref Pen 3mL Pk; strength: 1.34mg/mL
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; diabetes medication flag
Source prices (unrounded): $78.1410; ministry $78.1410
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02568012
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=107037Interchangeable products
Ozempic · DIN 02471469 · $78.1410
Semaglutide Injection · DIN 02567814 · $78.1410
Shortage status: active shortage (reported September 15, 2026, last updated September 17, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02568012
Limited Use, Reason for Use code 665 requiredMarketed · checked November 17, 2026
StatusLimited Use, Reason for Use code 665 required
Write on scriptReason for Use code 665 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ontario Limited Use criteria, code 665
Reason for Use code 665
For the treatment of adult patients with type 2 diabetes when adequate glycemic control is not achieved on the maximum tolerated dose of metformin or where metformin is contraindicated or inappropriate.
Semaglutide is not funded in combination with another glucagon-like peptide-1 receptor agonist (GLP-1 RA) or dipeptidyl peptidase-4 (DPP-4) inhibitor.
Injectable semaglutide is not funded in combination with oral semaglutide. Coverage is only provided for one dosage format.
Reimbursed dose: As per the product monograph
Coverage limit:
LU Authorization Period: Indefinite
Savings card: innoviCares lists Ozempic (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up. (innovicares.ca ↗)
1 brand, same coverage
Ozempic · DIN 02471469
Manufacturer: Novo Nordisk Canada Inc; listing date 2019-09-30
Health Canada: Marketed since 2018-02-22 · brand OZEMPIC · ATC A10BJ06 SEMAGLUTIDE · form Solution · route Subcutaneous · ingredients SEMAGLUTIDE 1.34 MG/ML · company Novo nordisk canada inc · schedule Prescription, Schedule d
DIN 02471469: Ozempic
Raw flags: insOH=Y, sec12=Y, sec3=Y
Item: 682006001; group id 761; item number 1866; lccId 00384; manufacturer id NOO
Source form: Inj Sol-Pref Pen 3mL Pk; strength: 1.34mg/mL
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; diabetes medication flag
Source prices (unrounded): $227.9400; ministry $78.1410
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02471469
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96058Interchangeable products
Apo-Semaglutide Injection · DIN 02568012 · $78.1410
Semaglutide Injection · DIN 02567814 · $78.1410
Shortage status: resolved shortage (ended January 17, 2024); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02471469
Limited Use, Reason for Use code 665 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 665 required
Write on scriptReason for Use code 665 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ontario Limited Use criteria, code 665
Reason for Use code 665
For the treatment of adult patients with type 2 diabetes when adequate glycemic control is not achieved on the maximum tolerated dose of metformin or where metformin is contraindicated or inappropriate.
Semaglutide is not funded in combination with another glucagon-like peptide-1 receptor agonist (GLP-1 RA) or dipeptidyl peptidase-4 (DPP-4) inhibitor.
Injectable semaglutide is not funded in combination with oral semaglutide. Coverage is only provided for one dosage format.
Reimbursed dose: As per the product monograph
Coverage limit:
LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Semaglutide Injection · DIN 02567814
Manufacturer: Dr. Reddy's Laboratories Inc.; listing date 2026-06-30
Health Canada: Marketed since 2026-05-06 · brand SEMAGLUTIDE INJECTION · ATC A10BJ06 SEMAGLUTIDE · form Solution · route Subcutaneous · ingredients SEMAGLUTIDE 1.34 MG/ML · company Dr reddy's laboratories ltd · schedule Prescription
Semaglutide Injection: Formulary list price $78.14 per unit (the source does not state the unit; exact figure $78.1410). What the ministry pays, not the patient.
Ministry pays: $78.1410 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 02567814: Semaglutide Injection
Raw flags: insOH=Y, sec12=Y, sec3=Y
Item: 682006001; group id 761; item number 1866; lccId 00384; manufacturer id DRR
Source form: Inj Sol-Pref Pen 3mL Pk; strength: 1.34mg/mL
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; diabetes medication flag
Source prices (unrounded): $78.1410; ministry $78.1410
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02567814
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=107019Interchangeable products
Apo-Semaglutide Injection · DIN 02568012 · $78.1410
Ozempic · DIN 02471469 · $78.1410
Shortage status: active shortage (reported July 20, 2026, last updated September 16, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02567814
Shortage record checked October 6, 2026
Rybelsus · DIN 02551012 · 1.5 mg · tablet
Limited Use, Reason for Use code 738 requiredMarketed · checked November 17, 2026
StatusLimited Use, Reason for Use code 738 required
Write on scriptReason for Use code 738 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ontario Limited Use criteria, code 738
Reason for Use code 738
For the treatment of adult patients with type 2 diabetes when adequate glycemic control is not achieved on the maximum tolerated dose of metformin or where metformin is contraindicated or inappropriate.
Semaglutide is not funded in combination with another glucagon like peptide-1 receptor agonist (GLP-1 RA) or dipeptidyl peptidase-4 (DPP-4) inhibitor.
Oral semaglutide is not funded in combination with injectable semaglutide. Coverage is only provided for one dosage format.
Maximum reimbursed dose: 1.5mg once daily.
Coverage limit:
LU Authorization Period: Indefinite
No interchangeable product listed in the Ontario extract
Rybelsus · DIN 02551012
Manufacturer: Novo Nordisk Canada Inc; listing date 2026-03-31
Health Canada: Marketed since 2026-03-13 · brand RYBELSUS · ATC A10BJ06 SEMAGLUTIDE · form Tablet · route Oral · ingredients SEMAGLUTIDE 1.5 MG · company Novo nordisk canada inc · schedule Prescription, Schedule d
DIN 02551012: Rybelsus
Raw flags: insOH=Y, sec12=Y, sec3=Y
Item: 682006010; group id 762; item number 1867; lccId 00428; manufacturer id NOO
Source form: Tab; strength: 1.5mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; diabetes medication flag
Source prices (unrounded): $7.5303; ministry $7.5303
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02551012
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103977
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02551012
Shortage record checked October 6, 2026
Rybelsus · DIN 02497581 · 3 mg · tablet
Limited Use, Reason for Use code 662 requiredMarketed · checked November 17, 2026
StatusLimited Use, Reason for Use code 662 required
Write on scriptReason for Use code 662 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ontario Limited Use criteria, code 662
Reason for Use code 662
For the treatment of adult patients with type 2 diabetes when adequate glycemic control is not achieved on the maximum tolerated dose of metformin or where metformin is contraindicated or inappropriate.
Semaglutide is not funded in combination with another glucagon like peptide-1 receptor agonist (GLP-1 RA) or dipeptidyl peptidase-4 (DPP-4) inhibitor.
Oral semaglutide is not funded in combination with injectable semaglutide. Coverage is only provided for one dosage format.
Maximum reimbursed dose: 3mg once daily.
Coverage limit:
LU Authorization Period: Indefinite
No interchangeable product listed in the Ontario extract
Rybelsus · DIN 02497581
Manufacturer: Novo Nordisk Canada Inc; listing date 2023-12-29
Health Canada: Marketed since 2020-04-19 · brand RYBELSUS · ATC A10BJ06 SEMAGLUTIDE · form Tablet · route Oral · ingredients SEMAGLUTIDE 3 MG · company Novo nordisk canada inc · schedule Schedule d, Prescription
DIN 02497581: Rybelsus
Raw flags: insOH=Y, sec12=Y, sec3=Y
Item: 682006006; group id 763; item number 1868; lccId 00379; manufacturer id NOO
Source form: Tab; strength: 3mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; diabetes medication flag
Source prices (unrounded): $7.5303; ministry $7.5303
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02497581
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98740
Shortage status: anticipated shortage (last updated June 5, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02497581
Shortage record checked October 6, 2026
Rybelsus · DIN 02551020 · 4 mg · tablet
Limited Use, Reason for Use code 739 requiredMarketed · checked November 17, 2026
StatusLimited Use, Reason for Use code 739 required
Write on scriptReason for Use code 739 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ontario Limited Use criteria, code 739
Reason for Use code 739
For the treatment of adult patients with type 2 diabetes when adequate glycemic control is not achieved on the maximum tolerated dose of metformin or where metformin is contraindicated or inappropriate.
Semaglutide is not funded in combination with another glucagon like peptide-1 receptor agonist (GLP-1 RA) or dipeptidyl peptidase-4 (DPP-4) inhibitor.
Oral semaglutide is not funded in combination with injectable semaglutide. Coverage is only provided for one dosage format.
Maximum reimbursed dose: 4mg once daily.
Coverage limit:
LU Authorization Period: Indefinite
No interchangeable product listed in the Ontario extract
Rybelsus · DIN 02551020
Manufacturer: Novo Nordisk Canada Inc; listing date 2026-03-31
Health Canada: Marketed since 2026-03-13 · brand RYBELSUS · ATC A10BJ06 SEMAGLUTIDE · form Tablet · route Oral · ingredients SEMAGLUTIDE 4 MG · company Novo nordisk canada inc · schedule Prescription, Schedule d
DIN 02551020: Rybelsus
Raw flags: insOH=Y, sec12=Y, sec3=Y
Item: 682006011; group id 764; item number 1869; lccId 00429; manufacturer id NOO
Source form: Tab; strength: 4mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; diabetes medication flag
Source prices (unrounded): $7.5303; ministry $7.5303
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02551020
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103978
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02551020
Shortage record checked October 6, 2026
Rybelsus · DIN 02497603 · 7 mg · tablet
Limited Use, Reason for Use code 663 requiredMarketed · checked November 17, 2026
StatusLimited Use, Reason for Use code 663 required
Write on scriptReason for Use code 663 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ontario Limited Use criteria, code 663
Reason for Use code 663
For the treatment of adult patients with type 2 diabetes when adequate glycemic control is not achieved on the maximum tolerated dose of metformin or where metformin is contraindicated or inappropriate.
Semaglutide is not funded in combination with another glucagon like peptide-1 receptor agonist (GLP-1 RA) or dipeptidyl peptidase-4 (DPP-4) inhibitor.
Oral semaglutide is not funded in combination with injectable semaglutide. Coverage is only provided for one dosage format.
Maximum reimbursed dose: 7mg once daily.
Coverage limit:
LU Authorization Period: Indefinite
No interchangeable product listed in the Ontario extract
Rybelsus · DIN 02497603
Manufacturer: Novo Nordisk Canada Inc; listing date 2023-12-29
Health Canada: Marketed since 2020-04-19 · brand RYBELSUS · ATC A10BJ06 SEMAGLUTIDE · form Tablet · route Oral · ingredients SEMAGLUTIDE 7 MG · company Novo nordisk canada inc · schedule Prescription, Schedule d
DIN 02497603: Rybelsus
Raw flags: insOH=Y, sec12=Y, sec3=Y
Item: 682006007; group id 765; item number 1870; lccId 00380; manufacturer id NOO
Source form: Tab; strength: 7mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; diabetes medication flag
Source prices (unrounded): $7.5303; ministry $7.5303
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02497603
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98741
Shortage status: active shortage (reported June 18, 2026, last updated July 7, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02497603
Shortage record checked October 6, 2026
Rybelsus · DIN 02551039 · 9 mg · tablet
Limited Use, Reason for Use code 740 requiredMarketed · checked November 17, 2026
StatusLimited Use, Reason for Use code 740 required
Write on scriptReason for Use code 740 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ontario Limited Use criteria, code 740
Reason for Use code 740
For the treatment of adult patients with type 2 diabetes when adequate glycemic control is not achieved on the maximum tolerated dose of metformin or where metformin is contraindicated or inappropriate.
Semaglutide is not funded in combination with another glucagon like peptide-1 receptor agonist (GLP-1 RA) or dipeptidyl peptidase-4 (DPP-4) inhibitor.
Oral semaglutide is not funded in combination with injectable semaglutide. Coverage is only provided for one dosage format.
Maximum reimbursed dose: 9mg once daily.
Coverage limit:
LU Authorization Period: Indefinite
No interchangeable product listed in the Ontario extract
Rybelsus · DIN 02551039
Manufacturer: Novo Nordisk Canada Inc; listing date 2026-03-31
Health Canada: Marketed since 2026-03-13 · brand RYBELSUS · ATC A10BJ06 SEMAGLUTIDE · form Tablet · route Oral · ingredients SEMAGLUTIDE 9 MG · company Novo nordisk canada inc · schedule Schedule d, Prescription
DIN 02551039: Rybelsus
Raw flags: insOH=Y, sec12=Y, sec3=Y
Item: 682006012; group id 766; item number 1871; lccId 00430; manufacturer id NOO
Source form: Tab; strength: 9mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; diabetes medication flag
Source prices (unrounded): $7.5303; ministry $7.5303
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02551039
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103979
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02551039
Shortage record checked October 6, 2026
Rybelsus · DIN 02497611 · 14 mg · tablet
Limited Use, Reason for Use code 664 requiredMarketed · checked November 17, 2026
StatusLimited Use, Reason for Use code 664 required
Write on scriptReason for Use code 664 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ontario Limited Use criteria, code 664
Reason for Use code 664
For the treatment of adult patients with type 2 diabetes when adequate glycemic control is not achieved on the maximum tolerated dose of metformin or where metformin is contraindicated or inappropriate.
Semaglutide is not funded in combination with another glucagon like peptide-1 receptor agonist (GLP-1 RA) or dipeptidyl peptidase-4 (DPP-4) inhibitor.
Oral semaglutide is not funded in combination with injectable semaglutide. Coverage is only provided for one dosage format.
Maximum reimbursed dose: 14mg once daily.
Coverage limit:
LU Authorization Period: Indefinite
No interchangeable product listed in the Ontario extract
Rybelsus · DIN 02497611
Manufacturer: Novo Nordisk Canada Inc; listing date 2023-12-29
Health Canada: Marketed since 2020-04-19 · brand RYBELSUS · ATC A10BJ06 SEMAGLUTIDE · form Tablet · route Oral · ingredients SEMAGLUTIDE 14 MG · company Novo nordisk canada inc · schedule Schedule d, Prescription
DIN 02497611: Rybelsus
Raw flags: insOH=Y, sec12=Y, sec3=Y
Item: 682006008; group id 767; item number 1872; lccId 00381; manufacturer id NOO
Source form: Tab; strength: 14mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; diabetes medication flag
Source prices (unrounded): $7.5303; ministry $7.5303
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02497611
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98742
Shortage status: active shortage (reported June 2, 2026, last updated July 7, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02497611
Shortage record checked October 6, 2026
Wegovy · DIN 02528525 · 4 mg/3 mL · injection solution-3mL pre-filled pen
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Savings card: innoviCares lists Wegovy (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up. (innovicares.ca ↗)
1 brand, same coverage
Wegovy · DIN 02528525
Manufacturer: Novo Nordisk Canada Inc; listing date 2026-08-31
Health Canada: Marketed since 2024-03-28 · brand WEGOVY · ATC A10BJ06 SEMAGLUTIDE · form Solution · route Subcutaneous · ingredients SEMAGLUTIDE 4 MG/3ML · company Novo nordisk canada inc · schedule Prescription, Schedule d
DIN 02528525: Wegovy
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 920000822; group id 959; item number 2276; lccId None; manufacturer id NOO
Source form: Inj Sol-3mL Pref Pen; strength: 4mg/3mL
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02528525
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101774Interchangeable products
Sevmia · DIN 02569582 · not recorded
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02528525
Limited Use, Reason for Use code 666 requiredDormant since July 24, 2026 · checked November 17, 2026 · What does dormant mean?
StatusLimited Use, Reason for Use code 666 required
Write on scriptReason for Use code 666 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ontario Limited Use criteria, code 666
Reason for Use code 666
For the treatment of adult patients with type 2 diabetes when adequate glycemic control is not achieved on the maximum tolerated dose of metformin or where metformin is contraindicated or inappropriate.
Semaglutide is not funded in combination with another glucagon-like peptide-1 receptor agonist (GLP-1 RA) or dipeptidyl peptidase-4 (DPP-4) inhibitor.
Injectable semaglutide is not funded in combination with oral semaglutide. Coverage is only provided for one dosage format.
Reimbursed dose: As per the product monograph
Coverage limit:
LU Authorization Period: Indefinite
Savings card: innoviCares lists Ozempic (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up. (innovicares.ca ↗)
1 brand, same coverage
Ozempic · DIN 02471477
Manufacturer: Novo Nordisk Canada Inc; listing date 2019-09-30
Health Canada: Dormant since 2026-07-24 · brand OZEMPIC · ATC A10BJ06 SEMAGLUTIDE · form Solution · route Subcutaneous · ingredients SEMAGLUTIDE 1.34 MG/ML · company Novo nordisk canada inc · schedule Schedule d, Prescription
DIN 02471477: Ozempic
Raw flags: insOH=Y, sec12=Y, sec3=Y
Item: 682006002; group id 760; item number 1865; lccId 00383; manufacturer id NOO
Source form: Inj Sol-Pref Pen 1.5mL Pk; strength: 1.34mg/mL
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; diabetes medication flag
Source prices (unrounded): $227.9400; ministry $78.1410
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02471477
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96059Interchangeable products
Semaglutide Injection · DIN 02567806 · $78.1410
Shortage status: resolved shortage (ended February 16, 2024); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02471477
Shortage record checked October 6, 2026
Health Canada lists this DIN as Dormant since July 24, 2026 — choose a marketed DIN from the same-category list.
Sevmia · DIN 02569582 · 4 mg/3 mL · injection solution-3mL pre-filled pen
Off-Formulary Interchangeable, not an ODB benefitApproved · checked November 17, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Sevmia · DIN 02569582
Manufacturer: Apotex Inc.; listing date 2026-08-31
Health Canada: Approved since 2026-06-29 · brand SEVMIA · ATC A10BJ06 SEMAGLUTIDE · form Solution · route Subcutaneous · ingredients SEMAGLUTIDE 4 MG/3ML · company Apotex inc · schedule Prescription
DIN 02569582: Sevmia
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 920000822; group id 959; item number 2276; lccId None; manufacturer id APX
Source form: Inj Sol-3mL Pref Pen; strength: 4mg/3mL
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $325.0480; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02569582
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=107181Interchangeable products
Wegovy · DIN 02528525 · not recorded
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02569582
Shortage record checked October 6, 2026
Health Canada lists this DIN as Approved since June 29, 2026 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary classes and how they are covered
Other drugs in the same formulary class (68:20:06 Incretin Mimetics) and how they are covered
Matched class: 68:20:06 Incretin Mimetics
Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment.
Covered without a code on the Ontario formulary: INSULIN GLARGINE & LIXISENATIDE
68:20:06 Incretin Mimetics
· 3 products · General benefit · strengths: 50mg & 12.5mg, 100mg & 25mg, 200mg & 50mg · Cap
Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 92:00
and 78 more
Full class listing
Related classes:
Same formulary class, not same indication: class membership alone does not establish equivalent uses.Other drugs whose Health Canada label lists a similar indication: major adverse cardiovascular events, type 2 diabetes
From Health Canada product monographs; label wording only, not a treatment recommendation.
Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ.
Covered without a code on the Ontario formulary: CANAGLIFLOZIN
ACARBOSE · Listed, not a benefit (2), Limited Use, codes 175, 176 (2)
INDICATIONS AND CLINICAL USE
• MAR-ACARBOSE (acarbose), as monotherapy, is indicated as an adjunct to prescribed
diet for the management of blood glucose levels in patients with type 2 diabetes mellitus
who are inadequately controlled by diet alone.
PM: https://pdf.hres.ca/dpd_pm/00053914.PDF; date not captured; DIN 02494078; fetched 2026-09-10
Product monographCANAGLIFLOZIN · General benefit
Add-On Combination in Patients with Established Cardiovascular Disease:
INVOKANA is indicated as an adjunct to diet, exercise, and standard of care therapy to reduce
the risk of major adverse cardiovascular events (cardiovascular death, nonfatal myocardial
infarction and nonfatal stroke) in adults with type 2 diabetes mellitus and established
cardiovascular disease (CVD).
PM: https://pdf.hres.ca/dpd_pm/00074895.PDF; date May 22, 2014; DIN 02425483; fetched 2026-09-10
Product monograph
Coverage source: ON formulary extract 2026-09-22
What the Health Canada label says it is for
1. Indications
OZEMPIC® is indicated for the once-weekly treatment of adult patients with type 2 diabetes to
improve glycemic control, in combination with:
• diet and exercise in patients for whom metformin is inappropriate due to contraindication
or intolerance.
• metformin, when diet and exercise plus maximal tolerated dose of metformin do not
achieve adequate glycemic control.
• metformin and a sulfonylurea, when diet and exercise plus dual therapy with metformin
and a sulfonylurea do not achieve adequate glycemic control.
• metformin or a sulfonylurea and a sodium-glucose cotransporter 2 inhibitor (SGLT2i),
when diet and exercise plus metformin or a sulfonylurea, in addition to an SGLT2i, do
not achieve adequate glycemic control.
• basal insulin with metformin, when diet and exercise plus basal insulin with metformin do
not achieve adequate glycemic control (see 14 Clinical Trials).
OZEMPIC® is indicated as an adjunct to diet, exercise, and standard of care to reduce the risk
of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction,
…
https://pdf.hres.ca/dpd_pm/00085314.PDF
PM date: 2026-07-13
Source product: OZEMPIC; DIN 02471469; fetched 2026-09-10
Product monograph posted by Health Canada; excerpt for lookup only.
Availability
Apo-Semaglutide Injection · DIN 02568020
Shortage status: active shortage (reported 2026-09-15, last updated 2026-09-17); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02568020
Semaglutide Injection · DIN 02567806
Shortage status: active shortage (reported 2026-07-20, last updated 2026-09-16); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02567806
Apo-Semaglutide Injection · DIN 02568012
Shortage status: active shortage (reported 2026-09-15, last updated 2026-09-17); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02568012
Semaglutide Injection · DIN 02567814
Shortage status: active shortage (reported 2026-07-20, last updated 2026-09-16); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02567814
Rybelsus · DIN 02497603
Shortage status: active shortage (reported 2026-06-18, last updated 2026-07-07); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02497603
Rybelsus · DIN 02497611
Shortage status: active shortage (reported 2026-06-02, last updated 2026-07-07); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02497611
Health Canada defines dormant products as: “products that were previously marketed in Canada but for which the manufacturer has suspended sale for period of at least 12 months.” (canada.ca, September 10, 2026 ↗)
Other review policies
For Wegovy, Sevmia: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.
For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy
Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.
For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)
Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.